title: Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
abstract: In this study, 54 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) were treated in a phase II, multicentric trial with ifosfamide-mesna 1500 mg/m2 IV days 1-3, idarubicin 12 mg/m2 IV day 1 and etoposide 100 mg/m2 IV day 1-3 (MIZE). Overall response was 72%; complete response (CR) and partial response (PR) were 46% and 26% respectively. In Stage I-II pts CR was 59% and in Stage III-IV pts CR was 40.5%. Patients who relapsed from an initial CR had a 64% CR rate when treated with MIZE, in contrast to refractory disease's patients who only had 19% CR (p = 0.004). The group of pts that had an objective response (CR + PR) to front line therapy had a 2 year survival rate of 55% compared with none for refractory disease (p = 0.029) after salvage therapy. Median survival for the entire group was 17.5 months. Better survival was seen in pts who were asymptomatic with low levels of LDH, previous CR, non high-grade histology, and limited disease stage at relapse. Toxicity was mainly hematologic: 91.5% had neutropenia, (56.5% grade III-IV), and 9.5% died from infectious complications. Other clinical toxicities including cardiac toxicity were negligible. MIZE chemotherapy was effective in patients with relapsed and refractory lymphoma and showed limited clinical and cardiac toxicity. Myelosupression was the most frequent single toxicity.
authors.affiliation: CEMIC: Centro de Educación Médica e Investigación Clínica, Universidad Nacional de Buenos, Buenos Aires, Argentina.
authors.forename: G
authors.initials: G
authors.lastname: Garay
authors.forename: J
authors.initials: J
authors.lastname: Dupont
authors.forename: M
authors.initials: M
authors.lastname: Dragosky
authors.forename: E
authors.initials: E
authors.lastname: Nucifora
authors.forename: R
authors.initials: R
authors.lastname: Cacchione
authors.forename: P
authors.initials: P
authors.lastname: Schnidrig
authors.forename: J
authors.initials: J
authors.lastname: Fernández
authors.lastname: Abel-Alzueta
authors.forename: D
authors.initials: D
authors.lastname: Riveros
authors.forename: V
authors.initials: V
authors.lastname: Noviello
authors.forename: R
authors.initials: R
authors.lastname: Bèguelin
authors.forename: R
authors.initials: R
authors.lastname: Campestri
authors.forename: C
authors.initials: C
authors.lastname: Albera
authors.forename: M
authors.initials: M
authors.lastname: Nicastro
authors.forename: E
authors.initials: E
authors.lastname: Triguboff
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007069:Ifosfamide / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D015080:Mesna / Q000008:administration & dosage; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy
chemical_list: D005047:Etoposide; D015080:Mesna; D007069:Ifosfamide; D015255:Idarubicin